Show Entire Article
I don't often write about micro caps, but given that the broader topic is bioterrorism and specifically something that the whole country was on pins and needles about not too long ago, I'm making an exception.
Late yesterday the federal government announced that it was canceling the contracts with two little companies, Emergent BioSolutions and PharmAthene , because it doesn't think the firms will have an anthrax vaccine ready within eight years. Shares of PIP, which has a market value of less than $50 million, are losing half of their value on the news, while EBS, which is a $400 million company, is taking a smaller hit.
Both companies put out press releases , but oddly PIP is waiting until Thursday afternoon to hold a conference call about the development. EBS apparently isn't doing one.
Page 1 of 3 | Next PageShow Entire Article
EBS News & Analysis
DATA IS REAL-TIME EXCEPT NOTED WITH *
* DATA DELAYED AT LEAST 15 MINUTES